<SEC-DOCUMENT>0001104659-25-010521.txt : 20250207
<SEC-HEADER>0001104659-25-010521.hdr.sgml : 20250207
<ACCEPTANCE-DATETIME>20250207160119
ACCESSION NUMBER:		0001104659-25-010521
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250207
DATE AS OF CHANGE:		20250207

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Maze Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001842295
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-94841
		FILM NUMBER:		25601575

	BUSINESS ADDRESS:	
		STREET 1:		171 OYSTER POINT BOULEVARD, SUITE 300
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		6508505070

	MAIL ADDRESS:	
		STREET 1:		171 OYSTER POINT BOULEVARD, SUITE 300
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Foresite Capital Fund IV, L.P.
		CENTRAL INDEX KEY:			0001704131
		ORGANIZATION NAME:           	
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		600 MONTGOMERY STREET, SUITE 4500
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94111
		BUSINESS PHONE:		415-877-4887

	MAIL ADDRESS:	
		STREET 1:		600 MONTGOMERY STREET, SUITE 4500
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94111
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Foresite Capital Fund IV, L.P. -->
          <cik>0001704131</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock, par value $0.001</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>01/31/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001842295</issuerCik>
        <issuerName>Maze Therapeutics, Inc.</issuerName>
        <issuerCusip>578784100</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>171 OYSTER POINT BOULEVARD, SUITE 300</com:street1>
          <com:city>SAN FRANCISCO</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94080</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Foresite Capital Fund IV, L.P.</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>2111917.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>2111917.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2111917.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>4.8</classPercent>
      <typeOfReportingPerson>PN</typeOfReportingPerson>
      <comments>Note to Row 5: 2,111,917 shares, except that Foresite Capital Management IV, LLC ("FCM IV"), the general partner of Foresite Capital Fund IV, L.P. ("FCF IV"), may be deemed to have sole power to vote these shares, and James Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole power to vote these shares.

Note to row 6: See response to row 5.

Note to Row 7: 2,111,917 shares, except that FCM IV, the general partner of FCF IV, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM IV, may be deemed to have sole power to dispose of these shares.

Note to row 8: See response to row 7.

Note to Row 11: This percentage is calculated based upon 43,776,978 Common Stock outstanding of Maze Therapeutics, Inc. (the "Issuer") as of January 31, 2025, as set forth in the Issuer's prospectus on Form 424(b)(4) filed with the Securities and Exchange Commission on January 31, 2025.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Foresite Capital Management IV, LLC</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>2111917.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>2111917.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2111917.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>4.8</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
      <comments>Note to Row 5: 2,111,917 shares, all of which are directly owned by FCF IV.  FCM IV, the general partner of FCF IV, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM IV, may be deemed to have sole power to vote these shares.

Note to row 6: See response to row 5.

Note to Row 7: 2,111,917 shares, all of which are directly owned by FCF IV.  FCM IV, the general partner of FCF IV, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM IV, may be deemed to have sole power to dispose of these shares.

Note to row 8: See response to row 7.

Note to Row 11: This percentage is calculated based upon 43,776,978 Common Stock outstanding of the Issuer as of January 31, 2025, as set forth in the Issuer's prospectus on Form 424(b)(4) filed with the Securities and Exchange Commission on January 31, 2025.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Foresite Capital Fund V, L.P.</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>345191.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>345191.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>345191.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>0.8</classPercent>
      <typeOfReportingPerson>PN</typeOfReportingPerson>
      <comments>Note to Row 5: 345,191 shares, except that Foresite Capital Management V, LLC ("FCM V"), the general partner of Foresite Capital Fund V, L.P. ("FCF V"), may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to vote these shares.

Note to row 6: See response to row 5.

Note to Row 7: 345,191 shares, except that FCM V, the general partner of FCF V, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to dispose of these shares.

Note to row 8: See response to row 7.

Note to Row 11: This percentage is calculated based upon 43,776,978 Common Stock outstanding of the Issuer as of January 31, 2025, as set forth in the Issuer's prospectus on Form 424(b)(4) filed with the Securities and Exchange Commission on January 31, 2025.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Foresite Capital Management V, LLC</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>345191.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>345191.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>345191.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>0.8</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
      <comments>Note to Row 5: 345,191 shares, all of which are directly owned by FCF V.  FCM V, the general partner of FCF V, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to vote these shares.

Note to row 6: See response to row 5.

Note to Row 7: 345,191 shares, all of which are directly owned by FCF V.  FCM V, the general partner of FCF V, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to dispose of these shares.

Note to row 8: See response to row 7.

Note to Row 11: This percentage is calculated based upon 43,776,978 Common Stock outstanding of the Issuer as of January 31, 2025, as set forth in the Issuer's prospectus on Form 424(b)(4) filed with the Securities and Exchange Commission on January 31, 2025.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>James Tananbaum</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>2457108.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>2457108.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2457108.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.6</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>Note to Row 5: 2,457,108 shares, of which 2,111,917 shares are directly owned by FCF IV and 345,191 shares are directly owned by FCF V.  Tananbaum is the managing member of each of FCM IV, which is the general partner of FCF IV, FCM V, which is the general partner of FCF V.  Tananbaum may be deemed to have sole power to vote these shares.

Note to row 6: See response to row 5.

Note to Row 7: 2,457,108 shares, of which 2,111,917 shares are directly owned by FCF IV and 345,191 shares are directly owned by FCF V.  Tananbaum is the managing member of each of FCM IV, which is the general partner of FCF IV, FCM V, which is the general partner of FCF V.  Tananbaum may be deemed to have sole power to dispose of these shares.

Note to row 8: See response to row 7.

Note to Row 11: This percentage is calculated based upon 43,776,978 Common Stock outstanding of the Issuer as of January 31, 2025, as set forth in the Issuer's prospectus on Form 424(b)(4) filed with the Securities and Exchange Commission on January 31, 2025.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Maze Therapeutics, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>171 OYSTER POINT BOULEVARD, SUITE 300, SAN FRANCISCO, CA, 94080</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>This Schedule is filed by Foresite Capital Fund IV, L.P., a Delaware limited partnership ("FCF IV"), Foresite Capital Management IV, LLC, a Delaware limited liability company ("FCM IV"), Foresite Capital Fund V, L.P., a Delaware limited partnership ("FCF V"), Foresite Capital Management V, LLC, a Delaware limited liability company ("FCM V") and James Tananbaum. The foregoing entities and individuals are collectively referred to as the "Reporting Persons."</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>c/o Foresite Capital Management

900 Larkspur Landing Circle, Suite 150Larkspur, CA 94939</principalBusinessOfficeOrResidenceAddress>
        <citizenship>See Row 4 of cover page for each Reporting Person.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>See Row 9 of cover page for each Reporting Person.</amountBeneficiallyOwned>
        <classPercent>See Row 11 of cover page for each Reporting Person.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>See Row 5 of cover page for each Reporting Person.</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>See Row 6 of cover page for each Reporting Person.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>See Row 7 of cover page for each Reporting Person.</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>See Row 8 of cover page for each Reporting Person.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>N</notApplicableFlag>
        <ownershipMoreThan5PercentOnBehalfOfAnotherPerson>Under certain circumstances set forth in the limited partnership agreements of FCF IV and FCF V and the limited liability company agreements of FCM IV and FCM V, the partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from the sale of, shares of the Issuer directly or indirectly owned by each such entity of which they are a partner or member.</ownershipMoreThan5PercentOnBehalfOfAnotherPerson>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <exhibitInfo>Agreement of Joint Filing

The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock of the Issuer shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G.

Date:  February 7, 2025

FORESITE CAPITAL FUND IV, L.P.

By: FORESITE CAPITAL MANAGEMENT IV, LLC
Its: General Partner

By: /s/ James Tananbaum
Name: James Tananbaum
Title: Managing Member


FORESITE CAPITAL MANAGEMENT IV, LLC

By: /s/ James Tananbaum
Name: James Tananbaum
Title: Managing Member


FORESITE CAPITAL FUND V, L.P.

By: FORESITE CAPITAL MANAGEMENT V, LLC
Its: General Partner

By: /s/ James Tananbaum
Name: James Tananbaum
Title: Managing Member


FORESITE CAPITAL MANAGEMENT V, LLC

By: /s/ James Tananbaum
Name: James Tananbaum
Title: Managing Member


JAMES TANANBAUM

By: /s/ James Tananbaum
Name: James Tananbaum</exhibitInfo>
    <signatureInformation>
      <reportingPersonName>Foresite Capital Fund IV, L.P.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ James Tananbaum</signature>
        <title>James Tananbaum, Managing Member of the General Partner</title>
        <date>02/07/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Foresite Capital Management IV, LLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ James Tananbaum</signature>
        <title>James Tananbaum, Managing Member</title>
        <date>02/07/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Foresite Capital Fund V, L.P.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ James Tananbaum</signature>
        <title>James Tananbaum, Managing Member of the General Partner</title>
        <date>02/07/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Foresite Capital Management V, LLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ James Tananbaum</signature>
        <title>James Tananbaum, Managing Member</title>
        <date>02/07/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>James Tananbaum</reportingPersonName>
      <signatureDetails>
        <signature>/s/ James Tananbaum</signature>
        <title>James Tananbaum</title>
        <date>02/07/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
